SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$164M
Q2 2019
Positions
54
Filings on Record
39
2019–present window
Filed
Aug 6, 2019
original filing

Summary

Birchview Capital, LP reported $164M in U.S.-listed holdings across 54 positions for Q2 2019.

The portfolio is heavily concentrated: CELG alone accounts for 39.2% of reported value.

Compared with Q1 2019, the fund opened 4 new positions and exited 4.

Portfolio Metrics

Turnover
+6.6%
vs prior filed quarter
Top-10 Concentration
+85.3%
share of reported value
Largest Position
+39.2%
Celgene
New / Exited
4 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 63.0%Other: 35.6%MLP: 1.4%ADR: 0.1%
  • Common Stock · 63.0% · $104M
  • Other · 35.6% · $58M
  • MLP · 1.4% · $2M
  • ADR · 0.1% · $120,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ACADACADIA PHARMACEUTICALS INCNEW+10.0K10.0K+$267,000$267,000
APLSUSDAPELLIS PHARMACEUTICALS INCNEW+8.0K8.0K+$203,000$203,000
MREOMEREO BIOPHARMA GROUP PLCNEW+47.6K47.6K+$120,000$120,000
BCRXBIOCRYST PHARMACEUTICALS INCNEW+20.0K20.0K+$76,000$76,000
DERMEURDERMIRA INCADDED+100.0K120.0K+$876,000$1M
GTHXEURG1 THERAPEUTICS INCADDED+25.0K40.0K+$977,000$1M
BMYBRISTOL-MYERS SQUIBB COADDED+24.0K44.0K+$1M$2M
CLEMENTIA PHARMACEUTICALS INCSOLD OUT−222.0K0−$6M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CELGCELGENE CORPhistory →COM39.22%$64M697.7K
2ACCELERATE DIAGNOSTICS INCCOM30.39%$50M2.18M
3ARRYEURARRAY BIOPHARMA INChistory →COM4.73%$8M168.0K
4NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.82%$5M55.0K
5QDEL*QUIDEL CORPhistory →COM1.76%$3M48.8K
6VERMILLION INCCOM1.69%$3M3.12M
7EQMUSDEQM MIDSTRM PRTNERS LP LTDhistory →UNIT LTD PARTN1.36%$2M50.0K
8BMYBRISTOL-MYERS SQUIBB COhistory →COM1.21%$2M44.0K
9OXFORD IMMUNOTEC GLOBAL PLCCOM1.17%$2M140.3K
10HROWHARROW HEALTH INCCOM0.95%$2M180.0K
11ARNAEURARENA PHARMACEUTICALS INCCOM0.78%$1M22.0K
12GTHXEURG1 THERAPEUTICS INCCOM0.75%$1M40.0K
13BDQMALBIREO PHARMA INCCOM0.75%$1M38.0K
14MASI*MASIMO CORPCOM0.72%$1M8.0K
15BIIBBIOGEN INCCOM0.71%$1M5.0K
16DERMEURDERMIRA INCCOM0.70%$1M120.0K
17AMARIN CORP PLCSPONS ADR NEW0.70%$1M59.0K
18VNDAVANDA PHARMACEUTICALS INCCOM0.69%$1M80.0K
19WRIGHT MEDICAL GROUP NVCOM0.54%$895,00030.0K
20VCYTVERACYTE INCCOM0.53%$877,00030.8K
21VYGRVOYAGER THERAPEUTICS INCCOM0.50%$817,00030.0K
22XLRNACCELERON PHARMA INCCOM0.47%$767,00018.7K
23ODONATE THERAPEUTICS INCCOM0.45%$734,00020.0K
24DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.43%$709,00045.0K
25DOVADOVA PHARMACEUTICALS INCCOM0.43%$705,00050.0K
26SOLENO THERAPEUTICS INCCOM0.41%$674,000240.6K
27ICPTUSDINTERCEPT PHARMACEUTICALS INCCOM0.40%$660,0008.3K
28ARVNARVINAS INCCOM0.40%$660,00030.0K
29PXDEURPIONEER NATURAL RESOURCES COCOM0.36%$585,0003.8K
30HTDCORCEPT THERAPEUTICS INCCOM0.34%$558,00050.0K
31MYGNMYRIAD GENETICS INCCOM0.34%$556,00020.0K
32XNCRXENCOR INCCOM0.31%$503,00012.3K
33LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.31%$503,00080.0K
34AM6AMICUS THERAPEUTICS INCCOM0.29%$474,00038.0K
35KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.25%$419,00070.0K
36ATRAGBXATARA BIOTHERAPEUTICS INCCOM0.24%$402,00020.0K
37IMGNEURIMMUNOGEN INCCOM0.24%$391,000180.0K
38NKTREURNEKTAR THERAPEUTICSCOM0.21%$338,0009.5K
39CLRUSDCONTINENTAL RESOURCES INCCOM0.20%$337,0008.0K
40ACADACADIA PHARMACEUTICALS INCCOM0.16%$267,00010.0K
41SIENUSDSIENTRA INCCOM0.15%$246,00040.0K
42ENCANA CORPCOM0.15%$244,00047.5K
43APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.12%$203,0008.0K
44EQTEQT CORPORATIONCOM0.11%$179,00011.3K
45TGTXTG THERAPEUTICS INCCOM0.08%$130,00015.0K
46CFRXEURCONTRAFECT CORPCOM0.07%$123,000240.2K
47YIELD10 BIOSCIENCE INCCOM0.07%$120,000123.6K
48MREOMEREO BIOPHARMA GROUP PLCADS0.07%$120,00047.6K
49CYTKCYTOKINETICS INCCOM0.07%$113,00010.0K
50XBITXBIOTECH INCCOM0.05%$76,00010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.